Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bio-Thera Conducts Simponi Phase III Trial

Study In Psoriatic Arthritis Patients Begins For BAT2506 Golimumab Biosimilar

Executive Summary

China’s Bio-Thera Solutions has announced the start of Phase III trials for its BAT2506 proposed biosimilar golimumab rival to Janssen’s Simponi.

You may also be interested in...



Bio-Thera Follows Hikma Deal With Sandoz Bevacizumab Alliance

Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.

Bio-Thera Kicks Off Phase III Trial For Stelara Rival

Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel